The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Quite a few that I personally know - party time
'm going to tomorrow nights presentation, anyone else?
BIG WEEK : Locked and loaded for a very wealthy future - two fingers to the detractors now.
Thanks to Purple11 on advfn, Silver Falcon soon to be ticker HEMO, will be involved in presentations. 'Spread the word' as follows, Investor Presentations Tue, 26th Sep 2017 07:00 RNS Number : 7722R Silver Falcon PLC 26 September 2017 Silver Falcon Plc (to become Hemogenyx Pharmaceuticals Plc) Investor presentations Silver Falcon Plc, (LSE: SILF), which has agreed to acquire the biotechnology company Hemogenyx Pharmaceuticals Limited ("Hemogenyx"), announces that it will be holding a series of meetings with investors regarding the opportunity presented to shareholders by the proposed acquisition of Hemogenyx LLC ("Hemogenyx"). The presentation will be led by Chief Executive Officer & Co-Founder of Hemogenyx, Dr Vladislav Sandler, with other Proposed Directors available for discussions after the formal presentation. The same presentation will be given at all events which are being held at different times to offer convenient options for those wishing to attend.
Getting exciting....GLA
Newtoallthis2015. Thank you for posting that link to a very interesting piece of information on and about our new company. That has put the new company & its name out their,a great piece of publicity for our new company.
of the link below: back in August, Moleculin Biotech, Inc. (NASDAQ:MBRX) developed an active drug component, the WP1122, which will be used in the company’s study for treating brain tumours. Upon announcement, the stock went from a low of 70 cents to a high of $3.40 and has now settled comfortably into the $2.75 range. Meanwhile, London-based biopharmaceutical company Hemogenyx has developed two products that can change the way we currently treat leukemia, lymphoma, and other blood diseases. The market potential of Hemogenyx has prompted Silver Falcon (LON:SILF), a London based shell to propose a reverse takeover which is just waiting for final approval at the AGM on October 4th, 2017. The new company will trade under the symbol (HEMO) starting October 6th. The company’s technologies help reduce the dangers and limitations of bone marrow and hematopoietic stem cell (HSC) transplantation. One of them can also remove the need of looking for a matched donor for the transplant. The first is the CDX Antibodies, which helps condition patients before the transplant without the toxicity of chemotherapeutical agents obtained from radiotherapy or chemotherapy. In short, this could possibly replace chemotherapy and its dreadful effects. These antibodies also specifically remove HSC/hematopoietic progenitors and can also eradicate malicious cells that are part of a leukemia subset. Its second product is the Hu-PHEC cells or postnatal human hemogenic endothelial cells. Hemogenyx uses these cells to produce cancer-free HSCs, which will be applied in transplants for best results in the treatment of blood cancers. According to Hemogenyx, these cells can also bring many advantages in the treatment due to them being easy to be separated. Hu-PHEC cells are also considered to be “healthy” since they do not build up mutations linked to blood cancer. Mergers and takeovers are part of this still-growing industry Mergers and acquisitions will always be part of any industry, including biotech, as evident by Silver Falcon’s reverse takeover of Hemogenyx, per DigitalLook. Silver Falcon issued 228.57 million shares, priced 3.5 pence per share, to Hemogenyx. Silver Falcon will also use the US biotech company’s name starting October 6th, when they will start trading again. Following the deal, Hemogenyx has raised approximately £3.0 million. The company thinks this will be sufficient in finishing the CDX antibodies’ preclinical development and in funding more preclinical development of some candidates for its Hu-PHEC cell therapy. The rise of impact investing and social entrepreneurship have driven growth towards this sector. The fact that these life sciences developments brought by biotech companies can be advantageous not just to countries with economic power but to developing nations as well “There’s definitely opportunity in the space. I’m very optimistic for the prospects for do
https://born2invest.com/articles/consider-buying-biotech-stocks/amp/
Lottery ticket question my friend: think of it this way HEMO has three phase trials to go through, humanised mice been used at study, now success means SP increase, including news flow over the next 12 month period short term, in other words a great investment into a novel procedure for blood cancers, very excited about the future
Huge relief that the long wait is nearly over, though the new name doesn't exactly slip off the tongue. Give me Silver Falcon any day!
Too right we want the warrants they could be worth a fortune in future
Is there anyone here who will respond to my question ?
and never denied- so what!
Now that we know that SILF is going somewhere, where do we think the mca can go ?? How high and what is possibly worth in future? This is biotech - so strictly speaking this is a a no joke of a mcap - most biotechs although not all have very high mcap - in particular when they are on their way up =- this looks like it is just starting - any ideas, thoughts ???
More info, was Buffalo based https://twitter.com/hemogenyx?lang=en Now registered address 5 Fleet Place(i.e SilverFalcon) Results next January https://beta.companieshouse.gov.uk/company/10118339 explanatory video from CEO https://www.indiegogo.com/projects/hemogenyx-a-new-treatment-for-blood-cancers#/
43North | Finals Pitch | HemoGenyx https://www.youtube.com/watch?v=3i6ziMwGt7M
Warrants are a great ploy to avoid a sell-off before news. Some will sell but the majority will want their warrants.
More details on the RTO from digitallook https://www.digitallook.com/news/aim-bulletin/silver-falcon-finally-swoops-for-biotech-hemogenyx-after-long-hunt--2852365.html
It does look like a good prospect for an RTO, probably much better market than the original financial stuff!
1 warrant for every 2 shares held if holding for two months from re-list as HEMO. Only the start of positive news flow over the next 12 months, watch this space.
What does 4p warrents mean in English terms I've 200k of theses fills like for ever !
Looks like shukan was right all along - he kept on saying he had faith, he knew what was going on - we need to be patient - turns out he was right - well done - at least one person on this board knew what he was talking about - let's know wait and see whether the falcon flies away - I woke up to a nice RNS from JOG - that one hurts real bad !!! Hopefully SILF will make up for this loss in the long term
Well done Shukan, Like you I too kept the faith. Some people really should not invest in shares. Risk = Reward, bring it on HEMO.
so all you muppets on here with doom and gloom wanting to hang the board of directors hold your heads in shame , i said keep the faith, Adrian working hard for share holders, considering cash position of SILF the deal is brilliantly executed, nice 4p warrants for existing share holders many do not deserve them following the disgraceful comments on this board, red faces all round , but not ME
Silver Falcon Plc (the "Company") Proposed acquisition of Hemogenyx LLC Change of Name to Hemogenyx Pharmaceuticals Plc Placing & Subscription to raise £2m Readmission to the Official List on 5 October 2017 Silver Falcon Plc (LSE: SILF) announces the agreement to acquire Hemogenyx Pharmaceuticals Limited for £8m (the "Acquisition") to be satisfied by the issue of 228,571,428 Consideration Shares at a price of 3.5p per share. Hemogenyx Pharmaceuticals Limited is the holding company for Hemogenyx LLC ("Hemogenyx"), a US based biotechnology company developing therapies to transform bone marrow and blood stem cell transplantation. These therapies will replace the need for existing methods of preparation of patients for a transplantation such as chemotherapy and radiation treatments, and will address the problem of finding a matching stem cell donor and reduce the risk of blood stem cell rejection after transplantation. In conjunction with the Acquisition, the Company has raised £2m through the issue of 57,142,857 New Ordinary Shares in a Placing and Subscription at a price of 3.5p per share, plus 1 for 2 warrants to qualifying shareholders over 62,021,429 New Ordinary Shares at 4.0p per share. Optiva Securities Ltd, Shard Capital Partners LLP and Peterhouse Corporate Finance Limited, acted as agents for the Company. In addition, 3,428,541 New Ordinary Shares will be issued to directors and advisers and up to 24,566,952 New Ordinary Shares will be available under options granted or to be granted to employees, proposed directors and advisory board members. As the Acquisition is classified as a reverse takeover for the purpose of the Listing Rules, completion of the Acquisition, together with the Placing and Subscription will require the cancellation of the Existing Ordinary Shares on the standard listing segment of the Official List and readmission of the Existing Ordinary Shares and the admission of the New Ordinary Shares to the standard listing segment of the Official List maintained by the FCA and to trading on the main market for listed securities of the London Stock Exchange. Completion of the Acquisition, Placing and Subscription is conditional upon the Resolutions being passed at the General Meeting of the Company, to be held at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London EC4M 7RD at 10.00 a.m. on 4 October 2017. Subject to passing of the Resolutions, it is expected that Admission will become effective, and that dealings in the Ordinary Shares will commence at 8.00 a.m. on 5 October 2017. The Company will then trade under the new company name of Hemogenyx Pharmaceuticals Plc and new ticker symbol "HEMO". The market capitalisation of the Company is expected to be £12.46m on Admission. HIGHLIGHTS · Hemogenyx is a preclinical stage biopharmaceuti